AV 001

Drug Profile

AV 001

Alternative Names: AV001

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Avadel Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Unspecified

Most Recent Events

  • 05 Jan 2017 Clinical trials in Undefined indication in USA (Parenteral)
  • 05 Jan 2017 Avadel Pharmaceuticals announces intention to submit NDA with the US FDA in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top